Boyaci A, Gokce V, Topaloglu S, et al. Outcome of significant functional tricuspid regurgitation late after mitral valve replacement for predominant rheumatic mitral stenosis[J]. Angiology, 2007, 58(3): 336-342. [2]Januzzi J L, Troughton R. Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management[J]. Circulation, 2013, 127(4):? 500-507. [3]Vanderheyden M, Vrints C, Verstreken S, et al. B-type natriuretic peptide as a marker of heart failure:? new insights from biochemistry and clinical implications[J]. Biomark Med, 2010, 4(2): 315-320. [4]Heart Failure Society of America, Lindenfeld J, Albert N M, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline.[J]. J Card Fail, 2010, 16(6): e1-e194. [5]Troughton R W, Lewis L K, Yandle T G, et al. B-type natriuretic peptides:? looking to the future[J]. Ann Med, 2011, 43(3): 188-197. [6]张?, 张新超. ST2与心肌梗死和心力衰竭的关系[J].中国心血管杂志, 2012, 17(4): 314-316. [7]Miller A M, Liew F Y. The IL-33/ST2 pathway--A new therapeutic target in cardiovascular disease[J]. Pharmacol Ther, 2011, 131(2): 179-186. [8]Dieplinger B, Egger M, Koehler W, et al. Prognostic value of soluble ST2 in an unselected cohort of patients admitted to an intensive care unit- The Linz Intensive Care Unit (LICU) study[J]. Clin Chim Acta, 2012, 413(5/6): 587-593. [9]Di-Somma S, Magrini L, Pittoni V, et al. In-hospital percentage BNP reduction is highly predictive for adverse events in patients admitted for acute heart failure:? the Italian RED Study[J]. Crit Care, 2010, 14(3): R116. [10]Casaclang-Verzosa G, Gersh B J, Tsang T S. Structural and functional remodeling of the left atrium:? clinical and therapeutic implications for atrial fibrillation[J]. J Am Coll Cardiol, 2008, 51(1): 1-11. [11]El-Zayat A. Potential use of Brain Natriuretic Peptide in patients with asymptomatic significant mitrial stenosis[J]. Egyptian Heart Journal, 2014, 66(3):? 269-275. [12]Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension[J]. J Am Coll Cardiol, 1998, 31(1): 202-208. [13]Yamasaki N, Kondo F, Kudo T, et al. Severe tricuspid regurgitation in the aged:? atrial remodeling associated with long-standing atrial fibrillation[J]. J Cardiol, 2006, 48(6): 315-323. [14]Rehman S U, Mueller T, Januzzi J L Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure[J]. J Am Coll Cardiol, 2008, 52(18): 1458-1465. [15]Januzzi J L Jr, Peacock W F, Maisel A S, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea:? results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study[J]. J Am Coll Cardiol, 2007, 50(7): 607-613. [16]Boisot S, Beede J, Isakson S, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure[J]. J Card Fail, 2008, 14(9): 732-738.